- Previous Close
0.0174 - Open
0.0174 - Bid 0.0170 x --
- Ask 0.0208 x --
- Day's Range
0.0170 - 0.0174 - 52 Week Range
0.0118 - 0.0328 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
6.534M - Beta (5Y Monthly) 2.01
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
spagonanomedical.seRecent News: 7UX.F
View MorePerformance Overview: 7UX.F
Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 7UX.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 7UX.F
View MoreValuation Measures
Market Cap
6.68M
Enterprise Value
3.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
29.47
Price/Book (mrq)
1.69
Enterprise Value/Revenue
18.10
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.64%
Return on Equity (ttm)
-32.67%
Revenue (ttm)
6.98M
Net Income Avi to Common (ttm)
-34.1M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
39.95M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-24.77M